Chinese drugmaker Haixi Pharma shares surged 103% in Hong Kong grey market.
Haixi Pharmaceuticals was established in Fuzhou in March 2012. Haixi Pharma is a pharmaceutical enterprise built around the Marketing Authorization Holder (MAH) system, covering the entire industry value chain from R&D, clinical research, and manufacturing to commercialization.